

National Stem Cell Holding Appoints Kenneth Steiner, MD, MBA,
as Chief Operating Officer

MOUNTAINSIDE, N.J., June 3 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (Pink Sheets: NHGI) today announced the appointment of Kenneth D. Steiner, MD, MBA, as its Chief Operating Officer. Dr. Steiner brings with him a vast array of proven management and business skills. After establishing a private medical practice in 1983, Dr. Steiner served as a medical and business consultant to numerous Fortune 500 companies. Over the past 20 years, Dr. Steiner has developed a large multi-specialty, interdisciplinary physician group in Woodbridge, New Jersey.

Dr. Steiner received his MD degree from the University of Tennessee Medical School in 1979 and completed his internship and teaching fellowship at Harvard Medical School. He then served as an associate director of emergency services at Lincoln Hospital in New York City. In 1992, Dr. Steiner was board-certified by the American Board of Emergency Medicine and was elected a fellow of the American Academy of Emergency Medicine. In 1998, Dr. Steiner received his MBA from the University of Tennessee Business School, where he was also an instructor. Dr. Steiner is a former contributing editor of The Encyclopedia of Health Care Management. He joined National Stem Cell as COO in May 2008.

"I am privileged to join such an innovative biotech company as it makes the transition from development to commercialization phase. National Stem Cell has developed its first line of cosmetic pharmaceuticals ("cosmosuticals") based on a patented biomaterial made from the secretions of specialized cell lines. Through its ownership of the skin care company ProteoDerm Inc., National Stem's unique formulations can be applied to the outer surface of the skin to replace damaged and missing proteins, as well as enhance the natural formation of collagen," said Dr. Steiner. "These anti-wrinkling and anti-aging products are unlike anything I've seen on the market today. I look forward to the product line's official launch in the third quarter of 2008."

National Stem Cell President Michael Cohen added, "Dr. Steiner combines over 30 years as a medical professional with an astute background in the financial industry. He has previously served as a medical consultant for a number of publicly traded Fortune 500 companies and will play a pivotal role in helping us become a fully reporting company." With the addition of Dr. Steiner, we look forward to capitalizing on the many commercial opportunities evolving from our productive research and development division."

About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a biotechnology company emerging from the R&D stage into the commercialization stage and is focused on developing therapeutics based upon the use of human cells and their derivatives. Its mission is to achieve a leadership position in

- 1) development of cell therapies for disease and injury;
- 2) stem cell and reproductive cell/tissue laboratory services including processing and banking; and
- 3) biomarkers, cell derivatives and cellular proteins.

It is developing a pipeline of proprietary cell therapeutics with particular focus on diabetes and cardiac disease. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These include but are not limited to: cancer, heart disease, diabetes, and auto immune conditions. Cell Therapy involves the introduction of healthy new cells to repair and replace damaged or lost cells. This therapy often referred to as "Regenerative Medicine" or "Cellular Medicine" provides much promise for the treatment of diseases previously regarded as incurable. In addition to its work with stem cell therapeutics, National Stem Cell is also working to leverage its commercial infrastructure and product development capabilities. Its investigational products are focused on the improvement of the quality of life for patients through therapeutics for their diseases and their families through reduced financial outlay and stress. Additionally it is developing an intellectual property portfolio in the area of cosmetics based on its recently discovered and isolated Secreted Matrix. The Company's multi-faceted R&D program has demonstrated results with over 10 patent applications and multiple products ready to enter the market. The Company is headquartered in Mountainside, NJ and has facilities at multiple academic institutions. For more information on National Stem Cell Holding, Inc., visit <http://www.nationalstemcell.com> or <http://www.pinksheets.com>.

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products and products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact:
Michael Cohen
Phone: (973) 544-6116
info@nationalstemcell.com

SOURCE National Stem Cell Holding, Inc.

CONTACT: Michael Cohen of National Stem Cell Holding, Inc., +1-973-544-6116,
info@nationalstemcell.com -0- Jun/03/2008 14:41 GMT

Last Updated: June 3, 2008 10:41 EDT